(A) Immunoblot detecting monoubiquitination of FANCD2 and chromatin-bound FANCL in cells exposed to mitomycin C (left panel) or cisplatin (right panel) in wild-type HCT116 (WT) and the indicated knockout/knockdown mutant cells. See also Fig. S4.
(B) Quantification of chromatin-bound FANCL (left panel of A) in wild-type HCT116 (WT), FANCG−/− + Ctrl shRNA, WT + shFANCF alone (shFANCF), FANCG−/− + shFANCF, and FANCL−/− cells exposed to mitomycin C. See also Fig. S4.
(C) Clonogenic survival of parental HCT116 (WT), FANCG−/− + Ctrl shRNA, FANCG−/− + shFANCF, and FANCL−/− cells treated with mitomycin C. See also Fig. S4.
(D) Clonogenic survival of parental DT40 (WT), FANCE−/−, FANCG−, and FANCE−/− FANCG− cells treated with cisplatin. See also Fig. S2C.
Error bars for chromatin-bound FANCL quantification (B) and clonogenic survivals (C and D) were derived from SDs from three or more independent tests.